Free Trial

IQVIA (NYSE:IQV) Price Target Raised to $180.00

IQVIA logo with Medical background

IQVIA (NYSE:IQV - Free Report) had its price target increased by Evercore ISI from $170.00 to $180.00 in a report published on Wednesday,Benzinga reports. Evercore ISI currently has an outperform rating on the medical research company's stock.

Other research analysts also recently issued reports about the stock. Barclays decreased their price target on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Mizuho reduced their price objective on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Finally, Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $222.45.

Read Our Latest Stock Analysis on IQV

IQVIA Stock Performance

Shares of NYSE IQV traded down $2.80 during mid-day trading on Wednesday, hitting $162.73. The company had a trading volume of 1,156,699 shares, compared to its average volume of 1,657,030. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. IQVIA has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a market capitalization of $28.15 billion, a price-to-earnings ratio of 22.17, a P/E/G ratio of 1.80 and a beta of 1.30. The stock's 50-day moving average price is $151.77 and its 200-day moving average price is $172.43.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same period last year, the firm posted $2.54 earnings per share. IQVIA's quarterly revenue was up 2.5% on a year-over-year basis. On average, sell-side analysts forecast that IQVIA will post 10.84 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. American National Bank & Trust bought a new stake in shares of IQVIA in the 1st quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new position in IQVIA in the 1st quarter worth about $33,000. Finally, ST Germain D J Co. Inc. boosted its holdings in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories

Analyst Recommendations for IQVIA (NYSE:IQV)

Should You Invest $1,000 in IQVIA Right Now?

Before you consider IQVIA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.

While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines